These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 9935127

  • 1. Effect of opioid blockade on insulin and growth hormone (GH) secretion in patients with polycystic ovary syndrome: the heterogeneity of impaired GH secretion is related to both obesity and hyperinsulinism.
    Villa P, Valle D, Mancini A, De Marinis L, Pavone V, Fulghesu AM, Mancuso S, Lanzone A.
    Fertil Steril; 1999 Jan; 71(1):115-21. PubMed ID: 9935127
    [Abstract] [Full Text] [Related]

  • 2. Impact of long-term naltrexone treatment on growth hormone and insulin secretion in hyperandrogenic and normal obese patients.
    Villa P, Fulghesu AM, De Marinis L, Valle D, Mancini A, Pavone V, Caruso A, Lanzone A.
    Metabolism; 1997 May; 46(5):538-43. PubMed ID: 9160821
    [Abstract] [Full Text] [Related]

  • 3. The growth hormone response to growth hormone-releasing hormone is blunted in polycystic ovary syndrome: relationship with obesity and hyperinsulinaemia.
    Lanzone A, Villa P, Fulghesu AM, Pavone V, Caruso A, Mancuso S.
    Hum Reprod; 1995 Jul; 10(7):1653-7. PubMed ID: 8582956
    [Abstract] [Full Text] [Related]

  • 4. Effect of the opioid blockade on the feeding-induced growth hormone response to growth hormone-releasing hormone in women with polycystic ovary syndrome.
    Guido M, Romualdi D, Mancini A, Lattanzi F, Villa P, Barini A, Lanzone A, De Marinis L.
    Fertil Steril; 2002 Nov; 78(5):994-1000. PubMed ID: 12413983
    [Abstract] [Full Text] [Related]

  • 5. Metabolic and endocrine consequences of acute suppression of FFAs by acipimox in polycystic ovary syndrome.
    Ciampelli M, Muzj G, Leoni F, Romualdi D, Belosi C, Cento RM, Lanzone A.
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5324-9. PubMed ID: 11701699
    [Abstract] [Full Text] [Related]

  • 6. Effect of feeding on growth hormone response to growth hormone-releasing hormone in polycystic ovarian syndrome: relation with body weight and hyperinsulinism.
    Villa P, Soranna L, Mancini A, De Marinis L, Valle D, Mancuso S, Lanzone A.
    Hum Reprod; 2001 Mar; 16(3):430-4. PubMed ID: 11228207
    [Abstract] [Full Text] [Related]

  • 7. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ, Laughlin GA, Bützow T, Maheshwari H, Baumann G, Yen SS.
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [Abstract] [Full Text] [Related]

  • 8. Influence of chronic Naltrexone treatment on growth hormone and insulin secretion in obese subjects.
    De Marinis L, Mancini A, Valle D, Bianchi A, De Luca AM, Fulghesu AM, Villa P, Mancuso S, Lanzone A.
    Int J Obes Relat Metab Disord; 1997 Nov; 21(11):1076-81. PubMed ID: 9368834
    [Abstract] [Full Text] [Related]

  • 9. Evidence of a distinct derangement of opioid tone in hyperinsulinemic patients with polycystic ovarian syndrome: relationship with insulin and luteinizing hormone secretion.
    Lanzone A, Fulghesu AM, Cucinelli F, Ciampelli M, Caruso A, Mancuso S.
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3501-6. PubMed ID: 8530590
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Involvement of ovarian steroids in the opioid-mediated reduction of insulin secretion in hyperinsulinemic patients with polycystic ovary syndrome.
    Guido M, Pavone V, Ciampelli M, Murgia F, Fulghesu AM, Apa R, Caruso A, Mancuso S, Lanzone A.
    J Clin Endocrinol Metab; 1998 May; 83(5):1742-5. PubMed ID: 9589685
    [Abstract] [Full Text] [Related]

  • 14. Insulin and GH secretion in adolescent girls with irregular cycles: polycystic vs multifollicular ovaries.
    Villa P, Rossodivita A, Fulghesu AM, Cucinelli F, Barini A, Apa R, Belosi C, Lanzone A.
    J Endocrinol Invest; 2003 Apr; 26(4):305-11. PubMed ID: 12841537
    [Abstract] [Full Text] [Related]

  • 15. Effect of metformin on the growth hormone response to growth hormone-releasing hormone in obese women with polycystic ovary syndrome.
    Guido M, Romualdi D, Giuliani M, Suriano R, Tienforti D, Costantini B, Lanzone A.
    Fertil Steril; 2005 Nov; 84(5):1470-6. PubMed ID: 16275246
    [Abstract] [Full Text] [Related]

  • 16. Opioid blockade effect on insulin beta-cells secretory patterns in polycystic ovary syndrome. Oral glucose load versus intravenous glucagon bolus.
    Ciampelli M, Fulghesu AM, Guido M, Murgia F, Muzj G, Belosi C, Fortini A, Cento R, Lanzone A.
    Horm Res; 1998 Nov; 49(6):263-8. PubMed ID: 9623517
    [Abstract] [Full Text] [Related]

  • 17. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
    Romualdi D, De Marinis L, Campagna G, Proto C, Lanzone A, Guido M.
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
    [Abstract] [Full Text] [Related]

  • 18. Growth hormone response to L-dopa and pyridostigmine in women with polycystic ovarian syndrome.
    Lee EJ, Lee BS, Lee HC, Park KH, Song CH, Huh KB.
    Fertil Steril; 1993 Jul; 60(1):53-7. PubMed ID: 8513959
    [Abstract] [Full Text] [Related]

  • 19. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF, Nilas L, Madsbad S, Holst JJ.
    Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.